Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

202131 citationsJournal Articlebronze Open Access

Authors

Guselkumab treatment provided greater efficacy vs. secukinumab at week 48 in most subpopulations of patients with psoriasis.

Good health and well-being

Published in: Journal of Dermatological Treatment

Volume 33, Issue 4, pp. 2317-2324

Field-Weighted Citation Impact: 1.72